RxDoctor Payments DataLook up a doctor →

Bennett Myers, MD

Neurology · Amherst, NYNPI 1437211414

Payments from drug & device makers

$3,773,385in general payments, 2019–2025

Across 2,269 payments — averaging $1663.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$2.7M
  • Neurology Practice Consortium GPO, LLC$311K
  • Novartis$130K
  • Genentech USA, Inc.$110K
  • Argenx US, Inc.$83K
  • Sanofi$81K
  • plus $355K from 54 others

What the payments were for

  • Consulting fees$78,40118%
  • Speaking & faculty fees$279,45865%
  • Travel & lodging$35,7948%
  • Food & beverage$37,6119%
  • Education$4350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.131$2,702,300
Neurology Practice Consortium GPO, LLC7$311,232
Novartis143$129,509
Genentech USA, Inc.266$110,113
Argenx US, Inc.78$83,089
Sanofi43$81,074
Biogen188$77,589
AbbVie(2 entities)152$57,509
Roche Products Limited110$56,277
AstraZeneca(2 entities)89$28,231
Amgen(2 entities)108$22,490
EMD Serono, Inc.105$18,375
Jazz Pharmaceuticals Inc.10$16,498
Sanofi US Services Inc.2$14,785
Tersera Therapeutics LLC2$10,000
Adamas Pharmaceuticals, Inc.22$7,864
UCB, Inc.58$7,729
Bristol Myers Squibb19$7,269
Janssen Scientific Affairs, LLC5$4,620
Merz North America, Inc.15$3,919
Hoffmann-la Roche Limited3$2,894
F. Hoffmann-la Roche AG1$2,400
Merz Pharmaceuticals, LLC20$2,131
Invivyd Inc2$1,455
MDD US Operations, LLC41$1,352
Teva Pharmaceuticals USA, Inc.64$989
TG Therapeutics, Inc.18$961
Banner Life Sciences, LLC6$874
Neurocrine Biosciences, Inc.49$814
Pfizer41$726
Tanabe Pharma America, Inc.35$567
Avanir Pharmaceuticals, Inc.25$555
Alnylam Pharmaceuticals Inc.28$490
Kyowa Kirin, Inc.21$473
GE HealthCare53$410
Lundbeck LLC22$357
Acadia Pharmaceuticals Inc24$319
Mallinckrodt Hospital Products Inc.15$317
Johnson & Johnson(2 entities)19$286
EDW Pharma, Inc.1$273
Nevro Corp.7$265
Otsuka America Pharmaceutical, Inc.14$264
Catalyst Pharmaceuticals, Inc.11$251
Eisai Inc.14$244
CSL Behring10$212
Lilly USA, LLC10$196
Revance Therapeutics, Inc.3$187
Biohaven Pharmaceutical Holding Company Ltd.11$170
Amneal Pharmaceuticals LLC10$145
E.r. Squibb & Sons, L.L.C.10$134
Grifols USA, LLC5$132
Abbott8$128
SK Life Science, Inc.5$123
Ipsen Biopharmaceuticals, Inc7$121
Supernus Pharmaceuticals, Inc.7$119
Mallinckrodt Enterprises LLC8$112
GRT US Holding, Inc.8$107
Greenwich Biosciences, Inc.7$107
Akcea Therapeutics, Inc.7$106
Averitas Pharma Inc.5$91

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,773,385 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$1,191,496
Medicare patients
400
Services billed
72,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone101$1,416,264
Gamunex-CImmune Globul G/Gly/Iga Avg 4683$613,155
RelyvrioSod Phenylbutyrat/Taurursodiol15$190,100
IngrezzaValbenazine Tosylate14$101,471
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$100,109
Dalfampridine ErDalfampridine17$20,437
Riluzole82$5,240
Gabapentin145$2,673
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$2,572
Pregabalin71$2,528
Carbidopa-LevodopaCarbidopa/Levodopa58$2,420
Rasagiline Mesylate18$1,708
Pyridostigmine Bromide32$1,153
Baclofen37$833
Tizanidine Hcl40$790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$132$613,15583 claims
Neurocrine Biosciences, Inc.Ingrezza$814$101,47114 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$145$1,15332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →